UroGen Pharma Q2 JELMYTO revenue up 11%, beats estimates

Reuters

Aug 07

<a href="https://laohu8.com/S/URGN">UroGen</a> Pharma <a href="https://laohu8.com/S/QTWO">Q2</a> JELMYTO revenue up 11%, beats estimates

Overview

UroGen Q2 JELMYTO revenue grows 11% yr/yr, beating analyst expectations
FDA approves ZUSDURI, marking a milestone in UroGen's product portfolio
Net loss for Q2 misses analyst estimates due to increased R&D and SG&A expenses

Outlook

Company expects full-year 2025 JELMYTO revenue of $94 to $98 mln
UroGen anticipates 2025 operating expenses of $215 to $225 mln
Company sees $5 bln+ market opportunity for ZUSDURI
UroGen aims to support ZUSDURI launch and drive sustained growth

Result Drivers

DEMAND GROWTH - JELMYTO sales increased 11% year-over-year, driven by 7% demand growth and favorable pricing
R&D - Expenses for the second quarter of 2025 were $18.9 million, including non-cash share-based compensation expense of $0.4 million

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$24.22 mln	$23.10 mln (8 Analysts)
Q2 Net Income	Miss	-$49.94 mln	-$40 mln (7 Analysts)
Q2 Operating Income	Miss	-$41.45 mln	-$33.50 mln (8 Analysts)
Q2 Pretax Profit	Miss	-$48.92 mln	-$40.40 mln (7 Analysts)
Q2 Basic EPS		-$1.05
Q2 Operating Expenses		$62.11 mln

Press Release: ID:nGNX3q8q7C

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557636875"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557636875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557636875?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557636875","market":"fut","top_or_hot":-1,"title":"UroGen Pharma Q2 JELMYTO revenue up 11%, beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/URGN\">UroGen</a> Pharma <a href=\"https://laohu8.com/S/QTWO\">Q2</a> JELMYTO revenue up 11%, beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>UroGen Q2 JELMYTO revenue grows 11% yr/yr, beating analyst expectations</p></li><li><p>FDA approves ZUSDURI, marking a milestone in UroGen's product portfolio</p></li><li><p>Net loss for Q2 misses analyst estimates due to increased R&amp;D and SG&amp;A expenses</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects full-year 2025 JELMYTO revenue of $94 to $98 mln</p></li><li><p>UroGen anticipates 2025 operating expenses of $215 to $225 mln</p></li><li><p>Company sees $5 bln+ market opportunity for ZUSDURI</p></li><li><p>UroGen aims to support ZUSDURI launch and drive sustained growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DEMAND GROWTH - JELMYTO sales increased 11% year-over-year, driven by 7% demand growth and favorable pricing</p></li><li><p>R&amp;D - Expenses for the second quarter of 2025 were $18.9 million, including non-cash share-based compensation expense of $0.4 million </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$24.22 mln</p></td><td><p>$23.10 mln (8 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-$49.94 mln</p></td><td><p>-$40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-$41.45 mln</p></td><td><p>-$33.50 mln (8 Analysts)</p></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$48.92 mln</p></td><td><p>-$40.40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$1.05</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$62.11 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX3q8q7C</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UroGen Pharma Q2 JELMYTO revenue up 11%, beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUroGen Pharma Q2 JELMYTO revenue up 11%, beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 20:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/URGN\">UroGen</a> Pharma <a href=\"https://laohu8.com/S/QTWO\">Q2</a> JELMYTO revenue up 11%, beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>UroGen Q2 JELMYTO revenue grows 11% yr/yr, beating analyst expectations</p></li><li><p>FDA approves ZUSDURI, marking a milestone in UroGen's product portfolio</p></li><li><p>Net loss for Q2 misses analyst estimates due to increased R&amp;D and SG&amp;A expenses</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects full-year 2025 JELMYTO revenue of $94 to $98 mln</p></li><li><p>UroGen anticipates 2025 operating expenses of $215 to $225 mln</p></li><li><p>Company sees $5 bln+ market opportunity for ZUSDURI</p></li><li><p>UroGen aims to support ZUSDURI launch and drive sustained growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DEMAND GROWTH - JELMYTO sales increased 11% year-over-year, driven by 7% demand growth and favorable pricing</p></li><li><p>R&amp;D - Expenses for the second quarter of 2025 were $18.9 million, including non-cash share-based compensation expense of $0.4 million </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$24.22 mln</p></td><td><p>$23.10 mln (8 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-$49.94 mln</p></td><td><p>-$40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-$41.45 mln</p></td><td><p>-$33.50 mln (8 Analysts)</p></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$48.92 mln</p></td><td><p>-$40.40 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$1.05</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$62.11 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX3q8q7C</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"乌龙制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLXAA8FCC:1","article_id":"2557636875","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557636875","pubTimestamp":1754569113,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UroGen Pharma Q2 JELMYTO revenue up 11%, beats estimatesOverviewUroGen Q2 JELMYTO revenue grows 11% yr/yr, beating analyst expectationsFDA approves ZUSDURI, marking a milestone in UroGen's product por","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药"},"translate_title":"UroGen Pharma第二季度JELMYTO收入增长11%，超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":0.9},"content_text":"UroGen Pharma Q2 JELMYTO revenue up 11%, beats estimatesOverviewUroGen Q2 JELMYTO revenue grows 11% yr/yr, beating analyst expectationsFDA approves ZUSDURI, marking a milestone in UroGen's product portfolioNet loss for Q2 misses analyst estimates due to increased R&D and SG&A expensesOutlookCompany expects full-year 2025 JELMYTO revenue of $94 to $98 mlnUroGen anticipates 2025 operating expenses of $215 to $225 mlnCompany sees $5 bln+ market opportunity for ZUSDURIUroGen aims to support ZUSDURI launch and drive sustained growthResult DriversDEMAND GROWTH - JELMYTO sales increased 11% year-over-year, driven by 7% demand growth and favorable pricingR&D - Expenses for the second quarter of 2025 were $18.9 million, including non-cash share-based compensation expense of $0.4 million Key DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$24.22 mln$23.10 mln (8 Analysts)Q2 Net IncomeMiss-$49.94 mln-$40 mln (7 Analysts)Q2 Operating IncomeMiss-$41.45 mln-$33.50 mln (8 Analysts)Q2 Pretax ProfitMiss-$48.92 mln-$40.40 mln (7 Analysts)Q2 Basic EPS-$1.05Q2 Operating Expenses$62.11 mlnPress Release: ID:nGNX3q8q7C(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}